An effective way to tackle cancer is here


  • Thousands of people might benefit from the new treatment method
  • Repurposing of isolating PKC protein drugs


Cancer to the immune system is called lymphoma or leukemia, this type of cancer affects the entire body’s bone marrow and lymph node. And as such kinds of cancers are spread throughout the body, surgery isn’t useful, thus the patients resort to chemotherapy. Even though there has been significant improvement in the treatment in the past ten years, lymphoma or leukemia often come back after a few months of treatment.

Effective options of treatment reduce overtime as tumors become resistant to chemotherapy after several rounds of treatment. For the majority of patients, a cure is out of the question and the final resort is to delay and control cancer for as long as possible, there needs to be an improvement in therapies that can find and eliminate the cells that are resistant to chemotherapy and make sure that the disease does not reoccur.

A study found out, if you treat a normal cell close to the cancer cell with a special drug solution know as Small Molecule Inhibitors, has a significant impact and an improved effect on broad ranges of chemotherapies. In a particular study it was found that combined therapies extended the chance of survival over 90% as compared to using chemotherapy alone.

Repurposing of drugs

                Similar to human tendencies, cancer cells do not like to live in isolation, they communicate with other cells in order to form microenvironment, and by the established communication the cancer cells constantly receive the supply of nourishment, in form of anchorage proteins, secretive growth factors, etc. These normal cells are known as “stroma”, they are essential factors of a cancer cell because they support tumor growth and survival. Without nourishment from stroma, cancer cells usually die.

Drugs that can block the function of the PKC protein and isolate the cancer cells have already been developed. These drugs weren’t considered to be a useful cancer treatment after the initial trial failures. Part of the reason for this failure is because these drugs were designed to directly kill cancer cells, but as the phenomenon of repurposing when the drugs were tested to perform the action of blocking proteins, they came out with flying colors.

This new treatment method can be beneficial for hundreds of thousands of people currently diagnosed or who are under observation or treatment. If these results can be replicated in further trials, it could become a new mainstay for cancer therapy.